Welcome to PharOS
Developing Value
Supplying Success
PharOS is a privately owned pharmaceutical company, developing and supplying generics and value added products with a global portfolio of more than 59 products and over 5.945 marketing authorizations worldwide.
1 3
Expertise
First to market
Last to Exit
PharOS is a multi-disciplinary organization, in recognition of the numerous different knowledge sets that are required for a proper pharmaceutical product development, registration and supply. Our expertise covers all aspects of product development from API sourcing up to market release.
2 3
The team
Our core competitive
advantage
At PharOS, we have a highly skilled workforce of more than 74 professionals all focused on developing and placing in the market top quality generic and other value added pharmaceuticals that improve the lives of patients to more than 65 countries.
3 3
29
PRODUCTS
LAUNCHED/DEVELOPED
30
PRODUCTS UNDER DEVELOPMENT /
UNDER REGISTRATION
60
Marketing Authorizations
Worldwide
84
COUNTRY
PRESENCE
OUR MISSION
FIRST TO LAUNCH, LAST TO EXIT
Our mission in PharOS is to materialize in the most efficient way our customers’ trust, by ensuring that their products will be among the first to be launched after patent expiry and the last ones to exit the market.
ABOUT PHAROS
TIMELINE
VIEW OUR STORY
FORCES UNITED
THE TEAM
OUR
WORLDWIDE
PRESENCE
MORE THAN 84 COUNTRIES
5945 MARKETING AUTHORIZATIONS
MORE THAN 350 CLIENTS
image/svg+xml
Presence
PRODUCTS
Today’s ideas...Tomorrow’s opportunities...
We provide affordable, high-quality medicines to more than 80 countries worldwide
VIEW ALL PRODUCTS
LATEST NEWS
Today’s ideas...Tomorrow’s opportunities...
Our mission in PharOS is to materialize in the most efficient way our customers trust, by ensuring that their products will be among the first to be launched after patent expiry and the last ones to exit the market.

17th Regulatory and Scientific Affairs Conference

17th Regulatory and Scientific Affairs Conference THE LANDMARK LONDON HOTEL, LONDON 25-26 January 2018
READ MORE